Linker length matters, Fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency

Journal of Biological Chemistry

Volumn 289, Issue 20, 2014, Pages 14392-14398

  Silacci, Michela ^a   Baenziger Tobler, Nadja ^a   Lembke, Wibke ^a   Zha, Wenjuan ^a   Batey, Sarah ^a,b   Bertschinger, Julian ^a   Grabulovski, Dragan ^a  

^a Covagen AG ^*  (Switzerland)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS;

BIOPHYSICAL PROPERTIES; FC FUSION PROTEINS; INFLAMMATORY CONDITIONS; INHIBITORY ACTIVITY; PHAGE DISPLAY TECHNOLOGY; PROINFLAMMATORY CYTOKINES; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

PROTEINS;

2C1 FC FUSION PROTEIN; HYBRID PROTEIN; INTERLEUKIN 17; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; PROTEIN KINASE FYN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; IC50; MOLECULAR GENETICS; SRC HOMOLOGY DOMAIN;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-17; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-FYN; RECOMBINANT FUSION PROTEINS; SRC HOMOLOGY DOMAINS;

EID: 84900992803     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.534578     Document Type: Article

References (31)

1. Beck, A., and Reichert, J. M. (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3, 415-416
2. Walsh, G. (2010) Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917-924
3. Czajkowsky, D. M., Hu, J., Shao, Z., and Pleass, R. J. (2012) Fc-fusion proteins: new developments and future perspectives. EMBO Mol. Med. 4, 1015-1028
4. Huang, C. (2009) Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr. Opin. Biotechnol. 20, 692-699
5. Kontermann, R. E. (2009) Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23, 93-109
6. Carter, P. J. (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp. Cell Res. 317, 1261-1269
7. Argos, P. (1990) An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J. Mol. Biol. 211, 943-958
8. Mohler, K. M., Torrance, D. S., Smith, C. A., Goodwin, R. G., Stremler, K. E., Fung, V. P., Madani, H., and Widmer, M. B. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548-1561
9. Viti, F., Nilsson, F., Demartis, S., Huber, A., and Neri, D. (2000) Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol. 326, 480-505
10. Grabulovski, D., Kaspar, M., and Neri, D. (2007) A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J. Biol. Chem. 282, 3196-3204
11. Binz, H. K., Amstutz, P., and Plückthun, A. (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23, 1257-1268
12. Gebauer, M., and Skerra, A. (2009) Engineered protein scaffolds as nextgeneration antiody therapeutics. Curr. Opin. Chem. Biol. 13, 245-255
13. Bertschinger, J., Grabulovski, D., and Neri, D. (2007) Selection of single domain binding proteins by covalent DNA display. Protein Eng. Des. Sel. 20, 57-68
14. Schlatter, D., Brack, S., Banner, D. W., Batey, S., Benz, J., Bertschinger, J., Huber, W., Joseph, C., Rufer, A., van der Klooster, A., Weber, M., Grabulovski, D., and Hennig, M. (2012) Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. MAbs 4, 497-508
15. Banner, D. W., Gsell, B., Benz, J., Bertschinger, J., Burger, D., Brack, S., Cuppuleri, S., Debulpaep, M., Gast, A., Grabulovski, D., Hennig, M., Hilpert, H., Huber, W., Kuglstatter, A., Kusznir, E., Laeremans, T., Matile, H., Miscenic, C., Rufer, A. C., Schlatter, D., Steyaert, J., Stihle, M., Thoma, R., Weber, M., and Ruf, A. (2013) Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. Acta Crystallogr. D Biol. Crystallogr. 69, 1124-1137
16. Mourlane, F., Toller, I., Brack, S., Grabulovski, D., and Bertschinger-Ehrler, J. (2012) Bispecific Fynomer-antibody fusion proteins targeting two epitopes on HER2. J. Clin. Oncol. 30, 2575
17. Ziolkowska, M., Koc, A., Luszczykiewicz, G., Ksiezopolska-Pietrzak, K., Klimczak, E., Chwalinska-Sadowska, H., and Maslinski, W. (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 164, 2832-2838
18. Arican, O., Aral, M., Sasmaz, S., and Ciragil, P. (2005) Serum levels of TNF-α, IFN-, IL-6, IL-8, IL-12, IL-γ17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005, 273-279
19. Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., and Fujiyama, Y. (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65-70
20. Brucklacher-Waldert, V., Steinbach, K., Lioznov, M., Kolster, M., Hölscher, C., and Tolosa, E. (2009) Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expression. J. Immunol. 183, 5494-5501
21. Nalbandian, A., Crispín, J. C., and Tsokos, G. C. (2009) Interleukin-17 and systemic lupus erythematosus: current concepts. Clin. Exp. Immunol. 157, 209-215
22. Genovese, M. C., Van den Bosch, F., Roberson, S. A., Bojin, S., Biagini, I. M., Ryan, P., and Sloan-Lancaster, J. (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebocontrolled, proof-of-concept study. Arthritis Rheum. 62, 929-939
23. Hueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., Psoriasis Study Group, Durez, P., Tak, P. P., Gomez-Reino, J. J., Rheumatoid Arthritis Study Group, Foster, C. S., Kim, R. Y., Samson, C. M., Falk, N. S., Chu, D. S., Callanan, D., Nguyen, Q. D., Uveitis Study Group, Rose, K., Haider, A., and Di Padova, F. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52-72
24. Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., and Banerjee, S. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366, 1190-1199
25. Carnemolla, B., Neri, D., Castellani, P., Leprini, A., Neri, G., Pini, A., Winter, G., and Zardi, L. (1996) Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer 68, 397-405
26. Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J. J., Garrone, P., Garcia, E., Saeland, S., Blanchard, D., Gaillard, C., Das Mahapatra, B., Rouvier, E., Golstein, P., Banchereau, J., and Lebecque, S. (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183, 2593-2603
27. Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., and Yamaguchi, T. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184, 1968-1976
28. Lubberts, E. (2008) IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41, 84-91
29. Wozniak-Knopp, G., Bartl, S., Bauer, A., Mostageer, M., Woisetschläger, M., Antes, B., Ettl, K., Kainer, M., Weberhofer, G., Wiederkum, S., Himmler, G., Mudde, G. C., and Rüker, F. (2010) Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng. Des. Sel. 23, 289-297
30. Coppieters, K., Dreier, T., Silence, K., de Haard, H., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Van de Wiele, C., Staelens, L., Hostens, J., Revets, H., Remaut, E., Elewaut, D., and Rottiers, P. (2006) Formatted anti-tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 54, 1856-1866
31. Allan, B., Chow, C. K., Huang, L., Liu, L., Lu, J., NG, K., Tetreault, J. W., and Werner, A. G. (June 21, 2007) Patent Number WO2007/070750